BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 25682340)

  • 1. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
    Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
    Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
    Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years.
    Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H
    J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
    Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
    Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
    Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
    Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
    Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
    Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
    Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
    Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
    Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
    Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
    Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.